S&P 500 7,662.52 ▲ 93.60 (+1.24%) DOW 53,023.25 ▲ 1,236.53 (+2.39%) NASDAQ 25,686.44 ▲ 314.43 (+1.24%) US Markets Open â€ĸ 11:27 AM ET

JNGHF

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Price Chart
Latest Quote

$6.40

+0.60 (+10.34%)
Current Price
Previous Close $5.80
Open $6.00
Day High $6.00
Day Low $6.00
Volume 400
Fetched: 2026-11-04T16:27:17
Stock Information
Note: Financial values converted from CNY to USD
Total Debt $10.20M
Cash Equivalents $5.83B
Revenue $4.93B
Net Income $1.33B
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
P/E Ratio 33.68
EPS (TTM) $0.19
Exchange PNK
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$3.95B
Sales$4.93B
Income$1.33B
Book/sh$1.52
Employees21K
Financial Ratios
Quick Ratio7.25
Current Ratio7.91
Debt/Eq0.10
EPS Growth TTM-15.30%
Returns & Margins
ROA7.77%
ROE13.94%
Gross Margin86.36%
Operating Margin22.99%
Profit Margin27.04%
Ownership
Institutional Ownership77.09%
Insider & Institutional transactions data not available
Valuation Ratios
P/B4.22
Analyst Data
Recommendationnone
Technical Indicators
SMA20$5.83
SMA50$5.89
RSI100.00
ATR0.0429
Shares Float3.73B
Volatility0.04
Rel Volume20.00
Performance History
Week+10.34%
Month+10.34%
YTD+4.92%
10 Years+4.92%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-11-03 $6.40 462
2026-11-02 $5.80 0
2026-10-30 $5.80 0
2026-10-29 $5.80 0
2026-10-28 $5.80 0
2026-10-27 $5.80 0
2026-10-26 $5.80 0
2026-10-23 $5.80 0
2026-10-22 $5.80 0
2026-10-21 $5.80 0
2026-10-20 $5.80 0
2026-10-19 $5.80 0
2026-10-16 $5.80 0
2026-10-15 $5.80 0
2026-10-14 $5.80 0
2026-10-13 $5.80 0
2026-10-12 $5.80 0
2026-10-09 $5.80 0
2026-10-08 $5.80 0
2026-10-07 $5.80 0
2026-10-06 $5.80 0
2026-10-05 $5.80 0
About Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

📰 Latest News
No news articles available at the moment. Check back later for updates on JNGHF.
Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Reconciled Cost Of Revenue $655,220,689 $577,951,952 $529,451,642 $523,653,030
Cost Of Revenue $655,220,689 $577,951,952 $529,451,642 $523,653,030
Total Revenue $4,750,374,258 $4,202,965,620 $3,427,269,012 $3,195,300,778
Operating Revenue $4,750,374,258 $4,202,965,620 $3,427,269,012 $3,195,300,778
Expenses
Interest Expense $2,155,069 $834,860 $886,679 $975,002
Total Expenses $3,459,292,157 $3,181,213,412 $2,732,537,862 $2,692,962,227
Other Non Operating Income Expenses $-42,409,821 $-48,201,796 $-36,465,050 $-21,547,220
Net Non Operating Interest Income Expense $115,693,522 $89,629,069 $70,661,904 $56,723,003
Total Other Finance Cost $107,524 $141,379 $112,866 $165,907
Interest Expense Non Operating $2,155,069 $834,860 $886,679 $975,002
Operating Expense $2,804,071,468 $2,603,261,460 $2,203,086,220 $2,169,309,197
Other Operating Expenses $39,589,281 $38,731,202 $32,929,898 $28,594,197
Selling And Marketing Expense $501,299,992 $834,301,691 $757,115,835 $669,085,328
General And Administrative Expense $603,775,949 $250,155,416 $214,508,126 $263,437,894
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $1,158,111,679 $951,673,424 $646,176,356 $586,692,573
Net Interest Income $115,693,522 $89,629,069 $70,661,904 $56,723,003
Interest Income $117,956,115 $90,605,308 $71,661,449 $57,863,912
Normalized Income $1,149,216,285 $937,006,668 $666,144,990 $599,830,503
Net Income From Continuing And Discontinued Operation $1,158,111,679 $951,673,424 $646,176,356 $586,692,573
Total Operating Income As Reported $1,350,194,952 $1,125,006,710 $737,411,207 $617,569,059
Net Income Common Stockholders $1,158,111,679 $951,673,424 $646,176,356 $586,692,573
Net Income $1,158,111,679 $951,673,424 $646,176,356 $586,692,573
Net Income Including Noncontrolling Interests $1,159,004,915 $951,743,657 $642,479,432 $572,990,353
Net Income Continuous Operations $1,159,004,915 $951,743,657 $642,479,432 $572,990,353
Pretax Income $1,307,785,131 $1,076,804,914 $700,946,157 $596,021,839
Special Income Charges $-16,031,507 $278,909 $-13,036,294 $-25,155,812
Interest Income Non Operating $117,956,115 $90,605,308 $71,661,449 $57,863,912
Operating Income $1,291,082,100 $1,021,752,208 $694,731,150 $502,338,551
Depreciation And Amortization In Income Statement $14,937,868 $11,781,395 $17,023,354 $5,689,756
Depreciation Income Statement $14,937,868 $11,781,395 $17,023,354 $5,689,756
Gross Profit $4,095,153,568 $3,625,013,668 $2,897,817,370 $2,671,647,748
Per Share
Diluted EPS $0.18 $0.15 $0.10 $0.09
Basic EPS $0.18 $0.15 $0.10 $0.09
Other
Tax Effect Of Unusual Items $1,141,892 $1,927,245 $-1,817,180 $-528,082
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $1,426,777,283 $1,177,596,562 $829,446,814 $697,455,656
Total Unusual Items $10,037,285 $16,594,001 $-21,785,814 $-13,666,013
Total Unusual Items Excluding Goodwill $10,037,285 $16,594,001 $-21,785,814 $-13,666,013
Reconciled Depreciation $126,874,368 $116,550,788 $105,828,164 $86,792,803
EBITDA (Bullshit earnings) $1,436,814,568 $1,194,190,562 $807,661,001 $683,789,643
EBIT $1,309,940,200 $1,077,639,775 $701,832,836 $596,996,840
Diluted Average Shares $981,450,575 $951,673,424 $950,259,347 $961,791,103
Basic Average Shares $973,203,091 $951,673,424 $950,259,347 $961,791,103
Otherunder Preferred Stock Dividend $0 $0 $0 $0
Minority Interests $-893,236 $-70,233 $3,696,924 $13,702,220
Tax Provision $148,780,216 $125,061,257 $58,466,725 $23,031,486
Other Special Charges $-608,734 $-810,704 $-474,973 $-822,088
Write Off $3,586,753 $-4,355,089 $-2,591,427 $3,947,618
Impairment Of Capital Assets $13,053,488 $4,886,884 $16,102,693 $22,030,282
Research And Development $1,045,485,420 $988,678,145 $744,016,824 $733,903,964
Selling General And Administration $1,105,075,940 $1,084,457,107 $971,623,961 $932,523,222
Fetched: 2026-11-03
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $8,175,914,584 $6,081,131,315 $5,570,412,870 $5,350,109,278
Total Assets $10,493,266,656 $7,529,796,863 $6,575,928,937 $6,363,617,871
Total Non Current Assets $2,760,005,368 $2,225,901,267 $1,876,910,886 $1,717,678,982
Other Non Current Assets $91,868,524 $71,956,319 $57,566,929 $66,465,936
Non Current Deferred Assets $31,872,942 $41,248,186 $50,465,802 $55,740,150
Non Current Deferred Taxes Assets $117,290,737 $56,647,288 $48,143,846 $35,879,645
Investmentin Financial Assets $221,166,873 $160,012,448 $113,601,264 $111,096,044
Goodwill And Other Intangible Assets $1,026,444,885 $755,428,002 $507,083,832 $330,554,190
Other Intangible Assets $1,026,444,885 $755,428,002 $507,083,832 $330,554,190
Current Assets $7,733,261,289 $5,303,895,597 $4,699,018,051 $4,645,938,889
Other Current Assets $82,378,274 $65,397,436 $50,170,396 $98,202,902
Prepaid Assets $158,682,906 $172,302,160 $183,392,312 $158,417,885
Inventory $432,304,427 $363,023,374 $347,540,071 $368,048,123
Other Receivables $118,801,588 $196,898,706 $207,059,845 $452,405,183
Accounts Receivable $772,954,394 $738,157,296 $780,153,144 $884,820,069
Allowance For Doubtful Accounts Receivable $-10,907,766 $-8,051,110 $-12,356,746 $-14,724,831
Gross Accounts Receivable $783,862,161 $746,208,406 $792,509,890 $899,544,900
Cash Cash Equivalents And Short Term Investments $6,168,139,700 $3,768,116,624 $3,130,702,283 $2,684,044,728
Cash And Cash Equivalents $6,151,042,069 $3,727,063,399 $3,115,826,175 $2,269,450,307
Cash Equivalents $15,172,856 $2,427,303 $978 $50,209
Cash Financial $6,135,869,213 $3,724,636,095 $3,115,825,197 $2,269,400,098
Debt
Total Debt $11,148,954 $16,545,074 $11,290,629 $204,226,924
Long Term Debt And Capital Lease Obligation $6,504,273 $10,368,433 $11,290,629 $14,847,728
Current Debt And Capital Lease Obligation $4,644,680 $6,176,641 - $189,379,196
Current Debt - - - $189,379,196
Liabilities
Total Liabilities Net Minority Interest $1,212,095,061 $607,571,702 $413,231,644 $594,441,133
Total Non Current Liabilities Net Minority Interest $255,508,931 $61,847,447 $29,701,511 $47,872,236
Other Non Current Liabilities $174,903,480 - - -
Non Current Deferred Taxes Liabilities $17,566,512 $17,588,911 $12,561,041 $15,085,995
Current Liabilities $956,586,130 $545,724,255 $383,530,133 $546,568,897
Other Current Liabilities $532,339 $528,153 $1,837,984 $1,708,809
Payables $664,165,632 $515,020,324 $351,941,236 $327,384,308
Other Payable $202,164,940 $155,431,052 $92,220,511 $44,019,196
Total Tax Payable $121,003,953 $64,129,593 $32,886,673 $17,899,657
Accounts Payable $340,996,738 $295,459,680 $226,834,052 $265,465,455
Equity
Common Stock Equity $9,202,359,468 $6,836,559,318 $6,077,496,702 $5,680,663,468
Total Equity Gross Minority Interest $9,281,171,595 $6,922,225,161 $6,162,697,293 $5,769,176,738
Stockholders Equity $9,202,359,468 $6,836,559,318 $6,077,496,702 $5,680,663,468
Retained Earnings $6,033,575,500 $5,086,212,665 $4,325,844,581 $3,832,841,453
Long Term Equity Investment $83,712,210 $100,078,672 $104,379,597 $115,323,962
Other
Ordinary Shares Number $996,831,027 $958,052,719 $958,052,719 $958,052,719
Share Issued $996,831,027 $958,052,719 $958,052,719 $958,052,719
Tangible Book Value $8,175,914,584 $6,081,131,315 $5,570,412,870 $5,350,109,278
Invested Capital $9,202,359,468 $6,836,559,318 $6,077,496,702 $5,870,042,664
Working Capital $6,776,675,158 $4,758,171,342 $4,315,487,918 $4,099,369,992
Capital Lease Obligations $6,504,273 $10,368,433 $11,290,629 $14,847,728
Total Capitalization $9,202,359,468 $6,836,559,318 $6,077,496,702 $5,680,663,468
Minority Interest $78,812,127 $85,665,844 $85,200,591 $88,513,271
Treasury Stock $289,724,972 $184,525,251 $163,983,418 $59,779,203
Additional Paid In Capital $1,893,522,653 $446,985,714 $448,789,866 $448,789,866
Capital Stock $996,831,027 $958,052,719 $958,052,719 $958,052,719
Common Stock $996,831,027 $958,052,719 $958,052,719 $958,052,719
Non Current Deferred Revenue $56,534,666 $33,890,103 $5,849,842 $17,938,513
Long Term Capital Lease Obligation $6,504,273 $10,368,433 $11,290,629 $14,847,728
Available For Sale Securities $221,166,873 $160,012,448 $113,601,264 $111,096,044
Net PPE $1,187,649,196 $1,040,530,351 $995,669,616 $1,002,619,056
Accumulated Depreciation $-838,851,314 $-742,885,098 $-656,525,020 $-576,957,626
Gross PPE $2,026,500,510 $1,783,415,449 $1,652,194,636 $1,579,576,682
Construction In Progress $301,334,467 $253,446,975 $165,356,734 $179,204,681
Other Properties $51,577,364 $54,019,119 $46,395,116 $46,263,320
Machinery Furniture Equipment $938,809,717 $879,016,125 $861,650,361 $822,335,685
Properties $734,778,963 $596,933,230 $578,792,425 $531,772,997
Inventories Adjustments Allowances $0 $0 $0 $0
Other Inventories $1,432,567 $1,382,818 $1,246,785 $4,043,403
Finished Goods $189,017,413 $189,317,150 $172,134,528 $172,645,637
Work In Process $93,688,828 $65,458,446 $60,952,769 $60,467,862
Raw Materials $148,165,618 $106,864,960 $113,205,989 $130,891,221
Other Short Term Investments $17,097,631 $41,053,225 $14,876,108 $414,594,421
Fetched: 2026-11-03
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $1,242,580,244 $819,061,273 $925,142,074 $-109,173,978
Operating Activities
Operating Cash Flow $1,687,424,476 $1,114,812,071 $1,147,990,516 $190,028,185
Cash Flowsfromusedin Operating Activities Direct $1,687,424,476 $1,114,812,071 $1,147,990,516 $190,028,185
Other Cash Paymentsfrom Operating Activities $-1,758,214,904 $-1,680,666,594 $-1,389,129,252 $-1,365,351,276
Classesof Cash Receiptsfrom Operating Activities $5,231,689,874 $4,275,698,361 $3,813,203,559 $2,897,854,083
Other Cash Receiptsfrom Operating Activities $184,474,069 $198,559,809 $194,573,737 $109,238,414
Investing Activities
Capital Expenditure $-444,844,232 $-295,750,797 $-222,848,442 $-299,202,162
Investing Cash Flow $-411,591,913 $-287,158,248 $183,577,660 $58,616,971
Financing Activities
Financing Cash Flow $1,168,722,880 $-232,880,775 $-472,256,638 $-47,875,616
Net Other Financing Charges $1,362,268,245 $-41,422,249 $-129,402,276 $-84,590,279
Cash Dividends Paid $-192,880,424 $-191,458,526 $-153,616,865 $-152,522,834
Other
Repayment Of Debt $-225,282,735 $-120,137,182 $-192,406,475 -
Issuance Of Debt $224,617,794 $120,137,182 $3,168,977 $189,237,497
End Cash Position $6,030,901,825 $3,640,434,146 $3,044,549,620 $2,183,355,749
Beginning Cash Position $3,640,434,146 $3,044,549,620 $2,183,355,749 $1,970,496,431
Effect Of Exchange Rate Changes $-54,087,764 $1,111,478 $1,882,333 $12,089,778
Changes In Cash $2,444,555,443 $594,773,048 $859,311,538 $200,769,539
Net Issuance Payments Of Debt $-664,941 $0 $-189,237,497 $189,237,497
Net Long Term Debt Issuance $-664,941 $0 $-189,237,497 $189,237,497
Long Term Debt Payments $-225,282,735 $-120,137,182 $-192,406,475 -
Long Term Debt Issuance $224,617,794 $120,137,182 $3,168,977 $189,237,497
Net Investment Purchase And Sale $30,411,987 $5,303,160 $403,394,713 $349,369,770
Sale Of Investment $30,411,987 $98,822,591 $405,960,769 $1,467,169,720
Net PPE Purchase And Sale $-442,003,900 $-292,461,408 $-219,817,053 $-296,166,406
Sale Of PPE $2,840,332 $3,289,389 $3,031,389 $3,035,756
Purchase Of PPE $-444,844,232 $-295,750,797 $-222,848,442 $-299,202,162
Change In Working Capital $323,576,022 $20,566,371 $357,734,137 $-431,101,169
Change In Other Current Assets $-60,665,848 $-3,475,572 $-14,789,155 $-3,320,311
Change In Payable $621,000,888 $100,837,850 $47,357,812 $-76,753,524
Change In Inventory $-71,975,952 $-20,370,188 $19,390,198 $-7,911,353
Change In Receivables $-164,783,066 $-56,425,720 $305,775,283 $-343,115,982
Other Non Cash Items $70,916,669 $13,959,728 $14,298,758 $10,926,591
Depreciation And Amortization $126,874,368 $116,550,788 $105,828,164 $86,792,803
Amortization Cash Flow $17,208,873 $10,102,276 $5,721,669 $3,376,517
Depreciation $109,665,495 $106,448,512 $100,106,495 $83,416,286
Gain Loss On Investment Securities $-17,435,856 $-19,899,834 $5,349,828 $-80,176,331
Gain Loss On Sale Of PPE $-114,638 $-68,168 $458,165 $-635,660
Net Income From Continuing Operations $1,159,004,915 $951,743,657 $642,479,432 $572,990,353
Taxes Refund Paid Direct $-418,595,709 $-343,954,237 $-235,466,415 $-244,973,491
Classesof Cash Payments $-3,125,669,689 $-2,816,932,053 $-2,429,746,628 $-2,462,852,408
Paymentson Behalfof Employees $-1,052,064,491 $-925,678,600 $-863,902,635 $-936,300,539
Paymentsto Suppliersfor Goodsand Services $-315,390,295 $-210,586,859 $-176,714,740 $-161,200,592
Receiptsfrom Customers $5,047,215,805 $4,077,138,553 $3,618,629,822 $2,788,615,670
Purchase Of Investment - $-93,519,431 $-2,566,056 $-1,117,799,950
Net Business Purchase And Sale - - - $5,413,606
Sale Of Business - - - $5,413,606
Fetched: 2026-11-03